Myasthenia gravis (MG) is arguably the best understood autoimmune disease, and its study has also led to fundamental appreciation of mechanisms of neuromuscular transmission. MG is caused by antibodies against the acetylcholine receptor (AChR), which produce a compromise in the end-plate potential, reducing the safety factor for effective synaptic transmission. It is clear that AChR antibody destruction of the postsynaptic surface is dependent on complement activation. A muscle-specific kinase has been recently found to be an antigenic target in MG patients without antibodies against the AChR. Autoantibody production in MG is a T-cell-dependent process, but how a breakdown in tolerance occurs is not known. In MG there is an interesting differential involvement of muscle groups, in particular, the extraocular muscles. This article reviews normal neuromuscular transmission, mechanisms of the autoimmune process of MG, and differential susceptibility of eye muscles to MG.
To understand the pathophysiology of myasthenia gravis (MG), a thorough appreciation of normal neuromuscular transmission and the underlying anatomy of the neuromuscular junction (NMJ) is imperative. [1] [2] [3] [4] [5] Although basic mechanisms of how the junction functions to transmit signals from nerve to muscle have been well established for decades, the last 10 years has seen an explosion of information regarding the molecular underpinning of transmission. In concert with these developments, appreciation of the intricacies of the autoimmune reaction underlying destruction of the postsynaptic surface of the muscle has expanded. This review will discuss the structure of the NMJ, how neuromuscular transmission occurs, and the pathogenesis of MG, as well as a summary of why certain muscle groups may be differentially involved by the disease.
ANATOMY AND PHYSIOLOGY OF THE NEUROMUSCULAR JUNCTION

Presynaptic Surface
As the motor nerve approaches a muscle it branches, innervating many muscle fibers and providing a single, unmyelinated nerve terminal to each of the fibers. The NMJ is a specialized synapse designed to transmit nerve impulses from the nerve terminal to muscle, via the chemical transmitter, acetylcholine (ACh), which is stored at the terminal in synaptic vesicles (Fig. 1) . These vesicles are aligned near release sites called ''active zones'' where calcium channels are arranged in parallel double rows. When an action potential reaches the nerve terminal, calcium channels of the P/Q-type (N-type channels also are localized to the presynaptic membrane) are activated, calcium enters the presynaptic terminal, and the local calcium concentration rises significantly, triggering the vesicles to release their contents. In the vertebrate NMJ, a typical nerve terminal action potential does not fully activate nerve terminal calcium channels, as the duration of the action potential is 1 ms, while nerve terminal calcium channels are activated with a time constant of 1.3 ms. 6 Therefore, enhancement of ACh release from the presynaptic nerve terminal can be achieved by increasing the nerve terminal action potential duration via blockade of delayed rectifier potassium channels with 3,4-diaminopyridine or inhibiting calcium uptake with quanidine, agents used in treatment of Lambert-Eaton syndrome.
The mechanism of relaying the calcium signal to synaptic vesicle fusion involves conformational changes in multiple proteins on the synaptic vesicle membrane and the plasma membrane of the nerve terminal. 4, 7, 8 The events leading to release of synaptic vesicle contents are being increasingly defined. Vesicles initially undergo a process called ''docking,'' in which they come into close proximity with the nerve terminal membrane and then undergo priming that allows them to respond to the calcium signal. During docking, munc18 dissociates from syntaxin and synaptophysin from synaptobrevin allowing the synaptic core complex to form. Three proteins, two on the plasma membrane (syntaxin and synaptic vesicle associated protein 25 or SNAP 25) and one on the synaptic vesicle membrane (synaptobrevin), are thought to form the docking complex. N-ethylmaleimide sensitive factor (NSF) and soluble NSF attachment protein (SNAP) associate to form a fusion complex with the docking proteins. N-ethylmaleimide sensitive factor, which is an ATPase, cross-links multiple core complexes into a network, and ATP hydrolysis leads to hemifusion of the vesicle and presynaptic nerve terminal membranes. Synaptotagmin likely acts as the calcium sensor, but other synaptic proteins may act in concert to perform Figure 1 Schematic of the mammalian neuromuscular junction, illustrating the major proteins located at the mammalian neuromuscular junction. The presynaptic nerve terminal contains synaptic vesicles (striped ovals), voltage-gated potassium (VGKC, triangles), and calcium channels (VGCC, gray rectangles). Acetylcholine receptor illustrated here in its pentameric structure. Voltage-gated sodium channels (striped rectangles), muscle-specific kinase (MuSK), rapsyn, utrophin, and the sarco-dystroglycan complex are located at the postsynaptic membrane. Details are discussed throughout the article. Objects are not drawn to scale. this function. The cytoplasmic portion of synaptotagmin includes two regions with high homology to the calcium and phospholipid-binding domains of a protein kinase. Synaptotagmin likely binds phospholipid of the plasma membranes and syntaxin. Binding of calcium to synaptotagmin may alter interactions of synaptotagmin with membrane lipids and syntaxin, allowing the membranes to fully fuse. Botulinum toxins are proteases that target several of the synaptic vesicle proteins and their investigation has greatly enhanced understanding of transmitter release. 9 How the synaptic release mechanism is capable of discharging synaptic vesicle contents in the extremely rapid fashion that it does is not known.
After releasing their contents to the synaptic cleft, synaptic vesicle membrane is recycled by a clathrinmediated mechanism. After reuptake of the vesicles, the clathrin-coated vesicles shed their coats and translocate into the interior. The vesicle membranes fuse with endosomes in the nerve terminal and new vesicles bud from the endosome. The new vesicles package ACh and other chemicals by active transport and translocate back to the active zone either by diffusion or by a cytoskeletal transport process.
Synaptic Cleft
Between the nerve and muscle plasma membranes lies a space of 50 nm called the ''synaptic cleft'' (Fig. 1) . The extracellular matrix of the synaptic cleft is a complex collection of proteins that regulate the synthesis of postsynaptic proteins and the concentration of acetylcholine esterase (AChE). The basement membrane is enriched with collagen and contains several forms of laminin, all of which bind to a-dystroglycan in the postsynaptic membrane. The laminins form a network in the synaptic space that anchors other extracellular matrix proteins. 10 Once released from the synaptic vesicles, diffusion of ACh across the cleft is rapid because of the small distance to cross and the high diffusion rate of ACh. 2 AChE is concentrated in the basal lamina of the postsynaptic membrane, and its action in hydrolyzing ACh, as well as the diffusion of ACh out of the cleft, leads to a rapid decline in ACh concentration. 11 This prevents the AChR from being activated more than once in response to ACh. AChE inhibitors, such as pyridostigmine and edrophonium, prolong the duration of action of ACh on the postsynaptic membrane, slowing the decay of the ACh-induced endplate current. 12 In postsynaptic diseases of neuromuscular transmission, AChE inhibition will serve to enhance ACh action and promote achievement of an end-plate potential that will lead to action potential generation. Schwann cells surrounding the nerve terminal have been found to secrete an acetylcholine binding protein, which may reduce the effective concentration of ACh in the synaptic cleft, and play a role in modulation of neuromuscular transmission. 13, 14 Postsynaptic Surface Once ACh traverses the synaptic cleft it binds the AChR concentrated across from the nerve terminal active zones (Fig. 1) . This binding results in opening of the AChR ion channel and the entry of cations, mainly sodium, into the muscle, leading to end-plate potential generation. When a certain threshold depolarization is achieved, voltage-gated sodium channels, at the bottom of the postsynaptic folds, open, allowing the entry of more sodium ions and generating the muscle action potential and contraction. 4 The postsynaptic skeletal muscle surface is characterized by invaginations of the plasma membrane, termed ''secondary synaptic folds.'' 2 The folds increase the surface area of the postsynaptic membrane and their architecture allows end-plate depolarization to be focused on their depths. 15 AChR concentrated at the tops of the secondary synaptic folds are anchored to the dystrophin-related protein complex through rapsyn, a protein involved in clustering of AChR at the NMJ during synapse development.
2 AChR clusters are connected to the cytoskeletal elements via associations with the dystroglycan and sarcoglycan protein complexes and utrophin. 16 Mice deficient in rapsyn do not effectively cluster AChR at the synapse. Some congenital myasthenia patients have been found to have rapsyn mutations or alterations in utrophin expression. [17] [18] [19] In addition to the anchoring system serving to concentrate AChR, muscle fiber nuclei near the NMJ preferentially express AChR subunit genes. 20 In addition to AChR, other proteins are differentially expressed at the NMJ. Na channels are highly concentrated in the membrane at the base of the synaptic folds by interaction with ankyrin, the sarcoglycan complex, the dystroglycan complex, dystrobrevins, and dystrophin/utrophin (Fig. 1 ). Utrophin and dystrobrevin also connect to a 1 syntrophin and a 2 syntrophin, which in turn associate with nitric oxide synthetase. 21, 22 Nitric oxide produced locally on the postsynaptic surface could serve a signaling function and has been shown to influence synaptogenesis. 23 The Acetylcholine Receptor The AChR is composed of four subunits and exists in two isoforms. [24] [25] [26] The adult AChR is composed of two a-subunits and one copy of each of the b-, d-, and e-subunits, while the fetal AChR has a g-subunit in place of the e-subunit. High amino acid sequence homology exists among the subunits of the AChR with each containing four a-helices, designated M1 to M4, that span the plasma membrane. The extracellular portions of the subunits consisting of the N-and C-terminal regions and the region between M2 and M3 form a large extracellular vestibule that surrounds the channel extracellular orifice. The regions between M1 and M2 and between M3 and M4 form a smaller vestibule around the intracellular orifice of the ion channel. 27, 28 The skeletal muscle nicotinic AChR has a large extracellular surface with the potential to form many epitopes for autoantibody binding and accommodate simultaneous binding of different antibodies.
In developing muscle, the fetal AChR is expressed along the entire fiber surface and contributes to the muscle being able to produce spontaneous contractions, which is critical to development. 29 With innervation fetal AChR is down-regulated and the adult receptor is expressed at the synapse. Only mammalian extraocular muscle is known to express fetal AChR protein at the synapse in adulthood 30, 31 ; however, reexpression of the fetal AChR in certain patients with congenital myasthenia prevents lethality of some mutations of AChR subunit genes. 32 Adult and fetal AChR can be distinguished by their electrophysiological characteristics. Adult channels have shorter mean open times and a single channel conductance that is 50% larger than that found with fetal channels. The differences between adult and fetal AChR channels are due to replacement of the g-with the e-subunit. Phosphorylation and other forms of posttranslational modification can alter properties of the AChR, and in particular, subunit phosphorylation appears to regulate agonistinduced desensitization. 24 
Neuromuscular Junction Formation and Muscle-Specific Kinase
The development of the NMJ requires a complex series of interactions between developing motor neurons and muscle fibers. 2, 11 Present understanding indicates that agrin, a protein synthesized by motor neurons and stably deposited into the synaptic basal lamina, stimulates a muscle-specific kinase (MuSK), a receptor tyrosine kinase, that is expressed selectively in skeletal muscle. This signal is thought to cluster significant postsynaptic proteins, including AChRs, at the NMJ (Fig. 1) . 33 This formulation is based on data showing that agrin can stimulate multiple aspects of postsynaptic differentiation in cultured myotubes, including the clustering and tyrosine phosphorylation of AChR. [34] [35] [36] Mice lacking agrin or MuSK fail to form neuromuscular synapses, and as a result, die at birth because of a failure to move or breathe. 37, 38 MuSK mutant mice do not concentrate AChR or other synaptic proteins at the NMJ, but rather these proteins are instead uniformly expressed along the muscle fiber.
The precise mechanism by which agrin activates MuSK is poorly understood. 39, 40 Agrin stimulates the rapid tyrosine phosphorylation of MuSK in myotubes, consistent with the idea that MuSK is a receptor, or a component of a receptor complex, for agrin. On the other hand, forced expression of MuSK in fibroblasts or myoblasts does not lead to its phosphorylation by agrin. 38 Also, recombinant agrin and MuSK in vitro do not bind, indicating that additional components that may be expressed in myotubes and skeletal muscle fibers, and not in myoblasts or fibroblasts, are essential for agrin to activate MuSK. As will be described later, MuSK has been identified as an antigenic target in MG patients seronegative for antibodies against the AChR.
SAFETY FACTOR FOR NEUROMUSCULAR TRANSMISSION
Compromise of the safety factor for neuromuscular transmission is common to all neuromuscular transmission disorders. 15 The safety factor is defined as the ratio of the end-plate potential amplitude to the difference between the membrane potential and the threshold potential for initiating an action potential. Normally, the nerve terminal releases enough ACh to induce an excitatory end-plate potential, which is greater than the threshold needed to initiate an action potential, and therefore, the safety factor is quite large. Quantal release, AChR conduction properties, AChR density, and AChE activity contribute to the end-plate potential and the safety factor. Sodium channel concentration at the postsynaptic surface affects the safety factor by making the action potential threshold easier to achieve. In addition, the synaptic fold's architecture, which allows current to be concentrated on the sodium channels, enhances the end-plate potential. AChE activity terminates the action of ACh and its inhibition will enhance AChR activation. Postsynaptic factors also influence the safety factor. Repetitive stimulation reduces transmitter release, which under normal conditions will reduce the end-plate potential but not enough to prevent action potential generation. In pathological situations, such as MG, this reduction may be enough to produce transmission failure.
IMMUNOPATHOLOGY MG meets strict criteria that define antibody-mediated, autoimmune disorders: (1) antibodies against the AChR can be detected in 80 to 90% of patients 41 ; (2) immunoglobulin G (IgG) is deposited at the NMJ, the site of pathology 42 ; (3) administration of IgG from MG patients to experimental animals reproduces the characteristic clinical features of the disease 43 ; (4) therapies that reduce the serum concentration of anti-AChR antibodies improve weakness 44 ; and (5) MG can be induced in animals by immunization with purified AChR, further supporting the concept that an immune response directed against the AChR is responsible for the disease in patients. 45 Autoantibodies in MG AChR antibodies are polyclonal, vary in light chain composition and subclass structure, and identify a heterogeneous epitope repertoire that varies among patients. 25, 26, 46, 47 AChR antibodies produce deficient neuromuscular transmission by three different mechanisms: (1) they bind to the AChR and alter function; (2) they promote endocytosis and accelerate the degradation rate of AChR; the effect of these antibodies in accelerating degradation is thought to result from their ability to cross-link the receptors 48 ; and (3) antibodies activate complement leading to destruction of the postsynaptic surface.
The most important mechanism of neuromuscular transmission compromise is antibody-mediated complement activation, and this statement is supported by several experimental observations. C3 activation fragments, C9, and the membrane attack complex can be detected at the NMJ in patients and experimental autoimmune MG of animals. 49, 50 Methods that deplete complement, block activation, or engineer defects in complement components protect animals against disease induction.
51-55 Skeletal muscle is protected from autologous complement-mediated injury by cell surface regulators located on their plasma membranes. 56, 57 These regulators are three proteins: the decay accelerating factor, the membrane cofactor protein, and the membrane inhibitor of reactive lysis. Collectively, these control proteins accelerate the decay of autologous C3 convertases and membrane attack complex that inappropriately assembles on self cell surfaces, promote the cleavage of uncomplexed autologous cell-bound complement fragments, and inhibit the formation of autologous attack complex, which brings about lysis of the postsynaptic membrane. Deficiency of decay accelerating factor in mice increases the severity of experimentally induced MG, suggesting that these complement regulators could modulate disease severity in humans. 58 Most pathogenic antibodies bind epitopes formed by the a-subunit in a region termed the ''main immunogenic region'' (MIR). 59 The most critical immunogenic area within the MIR is located on the extracellular N-terminal segment of the a-subunit. The MIR may be a particularly pathogenic region because (1) its location on surface of the AChR is easily accessed by antibody, (2) its amino acid structure is highly immunogenic, and (3) its location in densely packed AChR of the NMJ allows cross-linking and antigenic modulation. 25, 26 The immunodominance of this region might also be facilitated by the molecular mimicry between the MIR and epitopes on certain retroviruses. 60 In general, direct effects on AChR function are not considered to contribute significantly to MG pathology, but some patients have antibodies that bind the ACh binding site. These antibodies can contribute to myasthenic weakness and could cause acute myasthenic crisis. In animals, they produce a unique form of severe experimental autoimmune MG. 61 The first autoantibodies detected in MG patients were the striational antibodies, when MG patient serum was found to bind skeletal muscle in immunohistochemical studies. 62 The majority of these striational antibodies have been found to bind the structural protein titin. 63, 64 Antibodies against other skeletal muscle proteins, including the ryanodine receptor, myosin, tropomyosin, troponin, a-actinin, and actin, have been found among patients. 65 The pathogenic significance of these antibodies is not known, although ryanodine antibodies can compromise in vitro muscle contractility. The antibody profile of MG patients suggests differences in immunopathogenesis. Older-onset patients have higher frequencies of antibodies against the structural protein titin, and the disease is more severe. 64 Patients with thymoma also tend to be positive for not only titin antibodies but also ryanodine receptor antibodies, and such patients have been found to have associated myocarditis or myositis. 66 Up to 20% of patients with generalized MG are seronegative for AChR antibodies with 30% of these patients having autoantibodies against MuSK. [67] [68] [69] Ocular MG patients who are seronegative for the AChR are also negative for MuSK. MuSKpositive patients exhibit more severe disease than the AChR-positive patients, and some have been found to have muscle atrophy. Some MuSK antibodies compromise AChR channel function, but specific pathogenic mechanisms have not been defined. One would predict that MuSK antibodies compromise neuromuscular transmission by affecting AChR clustering at the NMJ.
Cellular Autoimmunity
Autoantibody production in MG is a T-cell-dependent process and a breakdown in tolerance toward self-antigens is the primary abnormality in MG. CD4 þ T-helper cells that are AChR-specific are crucial for the activation of B cells and for the synthesis of high-affinity IgG autoantibodies.
46 CD4 þ T cells in patients with MG regulate the production of anti-AChR antibodies, and suppressor T cells are present, which can decrease antibody production.
Several properties of the anti-AChR CD4 þ T cells are fundamental for understanding the pathogenesis of MG. CD4
þ T-helper cell receptors respond to antigens processed by antigen-presenting cells (APC) and associate with ''self'' major histocompatibility complex (MHC) class II molecules. T-cell receptor binds AChR only after it is processed by proteolytic cleavage and association with a MHC molecule by APC. The T-cell receptor grants antigen specificity to CD4 þ T cells. The requirement for MHC association restricts the number of epitopes that a T cell can recognize. Differences in MHC class II molecules have been shown to affect the severity of symptoms in experimental autoimmune MG and could be true in humans. 70 The AChR a-subunit contains the majority of T-cell recognition sites, although other subunits are recognized by T cells from patients. The epitopes on the a-subunit recognized by the T cell are distinct from the MIR recognized by antibodies. Similar to antibody production, the T-cell response is polyclonal and varies among MG patients. The T-cell-dependent nature of MG explains its association with human leukocyte antigen (HLA) antigens. [71] [72] [73] An increased association of HLA-A1, -B8, and -DRw3 (and -B12 antigen in Japan) occurs among MG women under 40 without thymoma. HLA-A3, -B7, and -DRw2 (and -A10 in Japan) occur with greater frequency in men after 40 without a thymoma. Restriction fragment length polymorphism analysis has demonstrated a link between MG and HLA-DQ, suggesting that HLA site is close to the coding region for the epitope of the AChR binding site.
With increasing disease duration, CD4
þ sensitization spreads to other parts of the AChR. The epitope repertoire of anti-AChR CD4 þ cells in MG patients is complex and characteristic of an individual patient. 46 A few sequence regions of anti-AChR CD4 þ cells are recognized in most or all MG patients. These sequences form CD4 þ epitopes that are both universal and immunodominant. These universal epitopes sensitize pathogenic CD4 þ cells and drive the synthesis of AChR antibodies. 47 CD4 þ T cells from MG patients respond in a remarkably heterogeneous fashion 74 and recognize epitopes from each of the AChR subunits including the adult e-subunit, the d-subunit, and the fetal g-subunit. Patients who have generalized weakness for greater than 5 years usually have CD4 þ T cells that recognize all subunits, whereas patients with weakness for shorter periods will only recognize few subunits of the AChR. These findings suggest enlargement of the CD4 þ epitope repertoire with time in generalized MG.
Studies of anti-AChR CD4 þ cells T-cell receptors from MG patients do not allow distinction between an initial pathogenic mechanism, which entails molecular mimicry, or the intervention of a superantigen. Superantigens are proteins found on viruses or bacteria that stimulate particularly powerful proliferative responses. Superantigens are not processed but directly bind to the class II MHC and to the T-cell receptor.
Cytokine Influences
Cytokines are peptides with intercellular signaling properties that regulate local and systemic immune responses, as well as other biological processes. Cytokines, secreted by different CD4 þ T-helper cell subsets after antigenstimulated activation, appear to play an important role in the pathogenesis of MG. 46 T-helper cells can be distinguished on the basis of the array of cytokines secreted. Th1 cells secrete proinflammatory cytokines such as interferon-g, interleukin-2, and tumor necrosis factor (TNF)-a. Th2 cells express anti-inflammatory/ regulatory cytokines including interleukin-4 and interleukin-10. Both Th1 and Th2 cell groups induce antibody synthesis by secreting cytokines that induce proliferation and differentiation of B cells. Some studies of cellular cytokine secretion in MG patients have shown that MG is associated with involvement of both Th1 and Th2 cells. 75, 76 Th1 cells are involved in the antibody response in MG and have an intricate epitope repertoire. In MG, the AChR is the sensitizing antigen and the target of the autoimmune Th1 cells. However, molecular mimicry between one AChR epitope and a microbial antigen might also play a role in the launching of the autoimmune response. Interleukin-4, secreted by Th2 cells, may be protective in experimental MG of animals as interleukin-4 has anti-inflammatory effects on both Th1 cells and APCs and acts as a growth-factor for transforming-growth factor (TGF)-b secreting cells.
TGF-b, which inhibits both cellular and humoral immunity, is also up-regulated in MG patients. Other cytokines that are being investigated in MG pathogenesis include TNF-a and TNF-b. Their function still needs further clarification; most likely they participate within the cytokine network, modulating the immune response. 46 The Thymus in MG Pathogenesis The thymus plays a key role in tolerance induction to self-antigens and in responsiveness of lymphocytes to foreign antigens. 46, 74 During development bone marrow stem cells appear in the thymic subcapsular epithelium, where a random process of gene rearrangements occurs in the regions that will code for the T-cell antigen receptor. The immature T cells pass through the thymic cortex, and those that recognize MHC antigens pass through to the medulla. The majority of immature T cells that do not recognize self MHC antigens are eliminated. During this stage in the thymic cortex, T cells, which would react toward self-antigens, are also removed; however, the mechanisms by which this occurs are not known. Once in the medulla, the T cells differentiate into helper and suppressor cells and eventually are released to the periphery.
Several findings indicate that the thymus is involved in MG pathogenesis. Pathological changes, specifically lymphoid follicular hyperplasia and thymomas, are frequent in patients with MG. 77 MG thymic tissue contains abnormally elevated amounts of mature T cells. Thymomas and myasthenic thymus are ''enriched'' for AChR-reactive T cells. 78 When myasthenic thymic tissue fragments are transplanted to severe combined immunodeficiency mice, they produce human antibodies, which bind to the AChR. 79 Most myasthenic thymuses contain B cells capable of producing AChR antibodies, particularly those hyperplastic thymuses with germinal centers. Normal and myasthenic human thymuses express gene transcripts and epitopes of all AChR subunits. [80] [81] [82] The expression of antigenically similar proteins to the AChR in the thymus would provide a source of antigen for autosensitization of T cells toward the skeletal muscle AChR. Further, thymectomy appears to improve the clinical course of patients with MG. 83 
THE DIFFERENTIAL INVOLVEMENT OF MUSCLE GROUPS BY MG
MG demonstrates a remarkable variation in muscle group involvement among patients. There is no better example of this than the involvement of ocular muscles. Weakness of the extraocular muscle (EOM) and the levator palpebrae are the initial signs of MG in the majority, ultimately occurs in nearly all, and may remain restricted to these muscles in 10 to 15% of patients. 84 One of the authors (H.J.K.) has recently provided detailed reviews of the preferential involvement of the EOM by MG, 85, 86 and the arguments are briefly summarized here.
The most simple, and least scientifically exciting, is that ocular muscle dysfunction leads to dramatic symptoms of double or blurred vision, which brings the patient to medical attention early. 87 Because of the precision required to maintain alignment of the visual axes, even a minor reduction of force generation produces visual compromise, in contrast to a small reduction in force generation of a limb muscle, which may not be readily appreciated or be ignored by a patient. Also, in extremity muscle, proprioceptive input may compensate to some extent by recruitment of additional motor units to perform a task. In ocular motor control, proprioception may not compensate in the same manner for reductions of force generation.
Several factors specific to the EOM place them at risk for MG involvement. Unique physiological properties of the oculomotor system may be of paramount importance in targeting of EOM by neuromuscular transmission abnormalities. The ocular motor neuron firing frequencies are extremely high, at times 400 to 500 Hz, which would exacerbate a transmission defect. EOM singly innervated fibers possess anatomical characteristics that would be predicted to make them susceptible to neuromuscular transmission block. The fibers have less prominent synaptic folds, and therefore one would predict fewer AChRs and sodium channels on the postsynaptic membrane. 88 A reduction in AChR and sodium channels would reduce the safety factor predisposing EOM to neuromuscular transmission failure. Na channel density varies between fast-twitch and slow-twitch fibers with fast-twitch fibers having higher densities in the region of the NMJ. 89 These differences could contribute to clinical involvement of muscle groups other than EOM by MG. 90 EOM also contains multi-innervated fibers that are similar to reptile tonic and intermediate fibers that have tonic contractile characteristics with the functional consequence that force generation is directly proportional to the membrane depolarization caused by the end-plate potential. Therefore, a safety factor does not exist for multi-innervated fibers, and any reduction of AChR would decrease contractile force of these fibers. 85, 86, 88 Also, the neuromuscular junctions have a scarcity (to complete absence) of junctional folds. 91 The autoimmune process of patients with ocular myasthenia does differ from patients with generalized disease. Ocular myasthenia patients have lower levels of AChR antibodies. 72 The intensity of T-cell responses to AChR epitopes of ocular myasthenia patients are lower than that of generalized patients, and they fluctuate over time. 92 Complement regulatory proteins are expressed at lower levels in EOM; therefore, a complement-mediated disease, such as MG, could be more likely to induce damage of these muscles. 93 The combination of mild autoimmune disease and physiologic susceptibility may be the explanation for the existence of purely ocular myasthenia.
The reasons for levator palpebrae involvement are not as clearly understood. The muscle is more similar to other skeletal muscle than to the EOM. The levator muscle fibers have twitch characteristics and some are highly fatigue-resistant, based on histological appearances, but there are no multi-innervated fibers. Nonimmune disorders of neuromuscular transmission also have a predilection for producing ptosis, suggesting that physiological reasons predispose them to neuromuscular transmission failure. The levator fibers are under constant neuronal stimulation during eye opening. This makes neuromuscular fatigue more likely to occur compared with other skeletal muscles. The junctional folds of levator NMJ are also sparse as in EOM and suggest a lower AChR number and a reduction in safety factor. 85 
SUMMARY
This review discussed the basic physiology of neuromuscular transmission and the structure that underlies communication between the nerve and muscle, the NMJ. Diseases of the NMJ and ion channels are of general interest because an understanding of their pathophysiology may provide insight into disorders at other neural synapses, such as epileptic or psychiatric diseases. MG serves as a model for the investigation of all autoimmune disorders.
